drugset / Trial / NCT03600649
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Phase 1
Unknown
50 enrolled
Salarius Pharmaceuticals, LLC
National Pediatric Cancer Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chromosomal translocations to Ewing sarcoma; AND dose expansion of the combination of seclidemstat with topotecan and cyclophosphamide in patients with Ewing sarcoma
Timeline
- Start
- 2018-06-04
- Primary completion
- 2025-09
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Subject | Seclidemstat | Small molecule | — | Oral |
| Subject | Topotecan | Small molecule | 0.75 mg/m2 | — |